User login
Key clinical point: Guselkumab led to sustained minimal or low disease activity (MDA/LDA) and remission across multiple disease domains over 1 year in patients with psoriatic arthritis (PsA) who had an inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR).
Major finding: At week 24, a greater proportion of patients receiving guselkumab vs placebo achieved MDA/LDA (14.8%-52.4% vs 3.1%-28.1%) and remission (3.7%-5.3% vs 0.0%-2.1%), according to composite indices. Most of the patients who achieved LDA/MDA or remission at week 24 (≥70%) maintained the response at week 48.
Study details: This post hoc analysis of the phase 3b COSMOS trial included 285 patients with PsA who had TNFi-IR and were randomly assigned to receive 100 mg guselkumab (n = 189) or placebo (n = 96) with 51 patients switching to guselkumab at week 24.
Disclosures: This study was supported by Johnson & Johnson Innovative Medicine. Several authors declared having ties with various sources, including being employees and having stock options or bond ownership in Johnson & Johnson or its subsidiaries.
Source: Gossec L, Baraliakos X, Aletaha D, et al. Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: Post hoc analysis of COSMOS. Rheumatology (Oxford). Published online October 22, 2024. Source
Key clinical point: Guselkumab led to sustained minimal or low disease activity (MDA/LDA) and remission across multiple disease domains over 1 year in patients with psoriatic arthritis (PsA) who had an inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR).
Major finding: At week 24, a greater proportion of patients receiving guselkumab vs placebo achieved MDA/LDA (14.8%-52.4% vs 3.1%-28.1%) and remission (3.7%-5.3% vs 0.0%-2.1%), according to composite indices. Most of the patients who achieved LDA/MDA or remission at week 24 (≥70%) maintained the response at week 48.
Study details: This post hoc analysis of the phase 3b COSMOS trial included 285 patients with PsA who had TNFi-IR and were randomly assigned to receive 100 mg guselkumab (n = 189) or placebo (n = 96) with 51 patients switching to guselkumab at week 24.
Disclosures: This study was supported by Johnson & Johnson Innovative Medicine. Several authors declared having ties with various sources, including being employees and having stock options or bond ownership in Johnson & Johnson or its subsidiaries.
Source: Gossec L, Baraliakos X, Aletaha D, et al. Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: Post hoc analysis of COSMOS. Rheumatology (Oxford). Published online October 22, 2024. Source
Key clinical point: Guselkumab led to sustained minimal or low disease activity (MDA/LDA) and remission across multiple disease domains over 1 year in patients with psoriatic arthritis (PsA) who had an inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR).
Major finding: At week 24, a greater proportion of patients receiving guselkumab vs placebo achieved MDA/LDA (14.8%-52.4% vs 3.1%-28.1%) and remission (3.7%-5.3% vs 0.0%-2.1%), according to composite indices. Most of the patients who achieved LDA/MDA or remission at week 24 (≥70%) maintained the response at week 48.
Study details: This post hoc analysis of the phase 3b COSMOS trial included 285 patients with PsA who had TNFi-IR and were randomly assigned to receive 100 mg guselkumab (n = 189) or placebo (n = 96) with 51 patients switching to guselkumab at week 24.
Disclosures: This study was supported by Johnson & Johnson Innovative Medicine. Several authors declared having ties with various sources, including being employees and having stock options or bond ownership in Johnson & Johnson or its subsidiaries.
Source: Gossec L, Baraliakos X, Aletaha D, et al. Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: Post hoc analysis of COSMOS. Rheumatology (Oxford). Published online October 22, 2024. Source